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LETTER TO THE EDITOR
 
EVALUATION OF THE “SYMBIOSYS” IMMUNOASSAY FOR THE SEROLOGICAL  
DIAGNOSIS OF CHAGAS DISEASE
São Paulo, December 6, 2011
Dear Sir,
For the laboratory diagnosis of Chagas disease several tests are commonly used. Sensitivity and specificity must always be taken into account, 
as well as the fact that these methods vary when we are dealing with an acute or chronic stage of the parasitosis3. Also, it is important to remember 
that the initial stage of Trypanosoma cruzi infection is characterized by the presence of the parasite in the blood and not by clinical or epidemiologic 
findings, for example. As for the diagnosis in the chronic stage, serological tests are usually the first choice.
In this context, new procedures are commonly proposed as new diagnosing tools, but it should be noted that they need to show further advances, 
especially in regard to sensitivity, specificity, ease of implementation, availability and cost.
To carry out the serological studies exemplifying these interests we mention the use of purified, recombinant, synthetic or excretory-secretory 
antigens with different strains of T. cruzi1,4,5,6,7,8. Some results were important and significant in attempts to show improvements in this new technique.
In the laboratories where we provide care and research activities, we often analyze the merits of submitted techniques for the purpose of providing 
assistance (Laboratório de Parasitologia do Instituto de Medicina Tropical da Universidade de São Paulo; Laboratório de Investigação Médica-
Parasitologia do Hospital das Clínicas, da Faculdade de Medicina da Universidade de São Paulo). Now, with the recent development of ELISA 
Anti- Chagas Sym (Symbiosys) enzyme immunoassay, which will probably soon be commercialized, and keeping a conduct adopted by us several 
times in the past, we feel it would be advisable to know the effectiveness of it in comparison with the Chagas Elisa III - Ebram2, widely used by us 
and, therefore, with which we are familiar.
The Anti-Chagas Sym immunoenzymatic assay (Symbiosys Diagnóstica Ltda., Lot 1016500010, used before the expiration date) uses microplates 
with wells that are coated with recombinant T. cruzi antigen, in which we place the samples. During incubation the antibodies possibly present in the 
samples tend to form a complex with the antigens of the microplate wells.
After aspiration and wash, all other components that are unlinked with the antigens are removed. In a second incubation the antigen-antibody 
complex is detected by the addition of a conjugate (anti-IgG antibodies conjugated with radish peroxidase) and the components that are connected 
in a non-specific manner are removed during the washing of the plate.
The enzyme activity fixed in the solid phase, acting with the chromogen solution generates an optical signal that is proportional to the amount of 
anti-Trypanosoma cruzi antibodies in the sample. The intensity of color is measured by spectrophotometer reading at 450 nm with a reference filter 
of 620/630.
Radish peroxidase is an enzyme isolated from wild radish that is capable of acting as antigens, also being used as a histochemical marker in 
optical and electronic microscopy. Its antigenicity allowed its use as an antigen marker in experimental immunology.
The Chagas Elisa III - Ebram immunoassay2 (EBRAM - Produtos Laboratoriais Ltda. Lot 02519A0827 used before the expiration date) uses 
microplates with wells coated with total extracts of T. cruzi, Tulahuen and Mn strains, including membrane antigens that are highly immunogenic. 
The wells’ treatment process is achieved through the use of new technology. A biological adhesive facilitates the immobilization of antigens thus 
increasing the plate stability. If the samples contain T. cruzi antibodies, there will be formation of a stable complex with the antigens that coat the wells.
The material attached in a non-specific manner will be removed by washing. During incubation with the conjugate, the human anti-IgG antibodies 
labeled with peroxidase will adhere to the formed complex. Finally, after incubation with the chromogenic substrate, the peroxidase attached to the 
complex will produce an optical sign that will allow us to select the samples that are T. cruzi positive. The enzymatic reaction will be ended with the 
addition of sulfuric acid. Then, the measurement of the color intensity at 450 nm in a colorimetric plate reader (ELISA Bio-Rad, model 2100) for both 
procedures were made and compared. The cut-off value is determined by multiplying the sum of the averages of the positive and negative controls 
by 0.22 (Sym) or 0.35 (Ebram), and the gray zone result is determined from the subtraction and addition of 10% of the cut-off for the two tests.
We used 158 serum samples from patients under care in the Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo aiming 
to establish a possible diagnosis of Chagas disease. We received only the medical requests, without any further information about the nature of the 
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cases. We found by both methods, 57 positive cases and 101 negative cases. Therefore, there was full agreement (100%), showing identical sensitivities 
and reliability, at least according to this assessment. We did not notice any operational difficulties. The cost is unknown to us.
In conclusion, we evaluated the sensitivity of the ELISA Anti-Chagas Sym (Symbiosys), a new tool for the serological diagnosis of Chagas disease 
that will probably be commercialized soon. This procedure uses Trypanosoma cruzi recombinant antigens and anti-IgG antibodies conjugated with 
radish peroxidase, with participation of a substrate-chromogen solution that generates an optical signal. For comparison we used the Chagas Elisa 
III-Ebram2, an already well known test which depends on total extracts of T. cruzi strains and membrane antigens that are highly immunogenic. In 
the comparison between the two tests we examined 158 sera to identify any that might be affected by Chagas disease. Fifty-seven tests were positive 
and 101 were negative, with a complete conformity between the two methods under consideration. We did not notice any operational difficulties in 
the 90 minutes it took to run the test. The ELISA Anti-Chagas Sym (Symbiosys) showed acceptable sensitivity. 
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